
    
      Subjects who received one dose of Menactra® or Menomune® in study MTA04, MTA12, MTA19
      (NCT00777790), or MTA21 (NCT00777257) will be eligible for enrollment in trial this study.
      All eligible subjects will provide a blood sample at Visit 1, after which their participation
      in the study will be terminated. An age-matched meningococcal-vaccine naïve control group
      will be recruited to provide a blood sample for baseline antibody level evaluation.

      No vaccine will be administered in this study.
    
  